<![CDATA[Epcoritamab Combo Receives Canadian Approval in R/R Follicular Lymphoma]]>

RegulatoryapprovedepcoritamablenalidomiderituximabPositive

AI Analysis

Summary

Health Canada approved epcoritamab in combination with lenalidomide and rituximab for relapsed/refractory grade 1 to 3a follicular lymphoma, supported by the EPCORE FL-1 trial data.

Clinical Trial Data

Outcome Details

Health Canada approved epcoritamab plus lenalidomide and rituximab for relapsed/refractory grade 1 to 3a follicular lymphoma

Importance:7/10

Sentiment:

0.80

regulatory approvalfollicular lymphomaCanadacombination therapyEPCORE FL-1

Related Companies

$HIT

Read the original article

Published by Cancer Network on September 24, 2026 4:00 PM

Read Original